Company & Sponsor Intelligence
AstraZeneca
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials2
Recruiting0
Completed2
Countries2
Therapeutic footprint
alzheimersdepression
Indexed studies
NCT02051335Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults
alzheimers · United KingdomPHASE1
alzheimers · United KingdomPHASE1
NCT00883493Efficacy and Safety of Quetiapine Versus Quetiapine Plus Lithium in Bipolar Depression
depression · ArgentinaPHASE3
depression · ArgentinaPHASE3
NCT00689559Drug Interaction Study Between AZD3480 and Aripiprazole in Healthy Subjects
alzheimers · SwedenPHASE1
alzheimers · SwedenPHASE1
Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →